Time for Paradigm Change in Management of Hepatocellular Carcinoma: Is a Personalized Approach on the Horizon?

Abraham, Jella‐Andrea; Golubnitschaja, Olga

doi:10.2217/pme-2016-0013

Cited by 11 publications

(13 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Practical implementation of novel and complex laboratory tests certainly should be considered from the viewpoint of their reasonability, cost-effectiveness and value added to a data interpretation. Smart laboratory investigation strategies and all-encompassing data interpretation are essential for an appropriate relationship between laboratory medicine and clinicians acting hand-in-hand as the decision makers responsible for better individual outcomes [70–75]. …”

Section: Predictive Preventive and Personalised Medicine (Pppm)mentioning

confidence: 99%

Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Predictive Preventive and Personalised Medicine (Pppm)mentioning

confidence: 99%

Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…MMPs, especially MMP‐2 and MMP‐9, are highly expressed in pathological tissues derived from patients with metastatic HCC after SIRT treatment . In recent years, patients with metastatic HCC have been treated with personalized management and tailored therapy . GP73 might be a potential target in tailored therapy targeting metastatic HCC.…”

Section: Discussionmentioning

confidence: 99%

Knockdown of Golgi phosphoprotein 73 blocks the trafficking of matrix metalloproteinase‐2 in hepatocellular carcinoma cells and inhibits cell invasion

Liu

Zhang

Zhou

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Golgi phosphoprotein 73 ( GP 73) has been regarded as a novel serum biomarker for the diagnosis of hepatocellular carcinoma ( HCC ) in recent years. It has been reported that the upregulation of GP 73 may promote the carcinogenesis and metastasis of HCC ; however, the mechanisms remain poorly understood. In this study, GP 73 correlates positively with matrix metalloproteinase‐2 ( MMP ‐2) in HCC ‐related cells and tissues. Further studies indicate that the knockdown of GP 73 blocks MMP ‐2 trafficking and secretion, resulting in cell invasion inhibition. Additionally, the knockdown of GP 73 induces the accumulation of intracellular MMP ‐2, which inhibits the phosphorylation of Src at Y416 and triggers the inhibition of SAPK / JNK and p53‐p21 signalling pathways through a negative feedback loop. Finally, the transactivation of MMP 2 was inhibited by the reduction in E2F1. This study reveals that GP 73 plays functional roles in the trafficking and equilibrium of epithelial‐mesenchymal transition ( EMT )‐related secretory proteins and that GP 73 serves as a new potential target for combating the metastasis of HCC .

show abstract

“…Hepatocellular carcinoma (HCC) is ranked as the fifth most common cancer but the second leading cause of all cancer-related mortalities [ 159 ]. This has been due to lack of effective screening programs and consequently late diagnosis, multifactorial origin with cumulative risk factors, complex carcinogenesis, tumour heterogeneity, unpredictable impacts of individual microenvironment on tumour development and progression, and, as the consequence, frequently untargeted therapy and cancer resistance towards currently applied treatment approaches [ 159 ]. Currently the “wait and treat” approach is inappropriate in the overall hepatocellular carcinoma management.…”

Section: Treatment Algorithm Tailored To Individual At Risk Of Non-communicable Diseasesmentioning

confidence: 99%

All around suboptimal health — a joint position paper of the Suboptimal Health Study Consortium and European Association for Predictive, Preventive and Personalised Medicine

et al. 2021

Self Cite

View full text Add to dashboard Cite

First two decades of the twenty-first century are characterised by epidemics of non-communicable diseases such as many hundreds of millions of patients diagnosed with cardiovascular diseases and the type 2 diabetes mellitus, breast, lung, liver and prostate malignancies, neurological, sleep, mood and eye disorders, amongst others. Consequent socio-economic burden is tremendous. Unprecedented decrease in age of maladaptive individuals has been reported. The absolute majority of expanding non-communicable disorders carry a chronic character, over a couple of years progressing from reversible suboptimal health conditions to irreversible severe pathologies and cascading collateral complications. The time-frame between onset of SHS and clinical manifestation of associated disorders is the operational area for an application of reliable risk assessment tools and predictive diagnostics followed by the cost-effective targeted prevention and treatments tailored to the person.This article demonstrates advanced strategies in bio/medical sciences and healthcare focused on suboptimal health conditions in the frame-work of Predictive, Preventive and Personalised Medicine (3PM/PPPM). Potential benefits in healthcare systems and for society at large include but are not restricted to an improved life-quality of major populations and socio-economical groups, advanced professionalism of healthcare-givers and sustainable healthcare economy. Amongst others, following medical areas are proposed to strongly benefit from PPPM strategies applied to the identification and treatment of suboptimal health conditions: Stress overload associated pathologies Male and female health Planned pregnancies Periodontal health Eye disorders Inflammatory disorders, wound healing and pain management with associated complications Metabolic disorders and suboptimal body weight Cardiovascular pathologies Cancers Stroke, particularly of unknown aetiology and in young individuals Sleep medicine Sports medicine Improved individual outcomes under pandemic conditions such as COVID-19.

show abstract

Time for Paradigm Change in Management of Hepatocellular Carcinoma: Is a Personalized Approach on the Horizon?

Cited by 11 publications

References 119 publications

Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016

Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016

Knockdown of Golgi phosphoprotein 73 blocks the trafficking of matrix metalloproteinase‐2 in hepatocellular carcinoma cells and inhibits cell invasion

All around suboptimal health — a joint position paper of the Suboptimal Health Study Consortium and European Association for Predictive, Preventive and Personalised Medicine

Contact Info

Product

Resources

About